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Abstract
Background: Platelet and blood coagulation abnormalities frequently occur in cancer patients. Fibrinogen is an
important hemostatic factor that regulates the hemostatic pathway. Hyperfibrinogenemia is increasing recognized
as an important risk factor influencing cancer development and outcome. However, few reports have investigated
the prognostic potential of fibrinogen for predicting the survival of gastric cancer (GC) patients. The primary aim of
this study was to evaluate the usefulness of preoperative serum fibrinogen as a biomarker for predicating tumor
progression and survival of patients with GC.
Patients and methods: This retrospective study was conducted in GC patients who underwent gastrectomy from
2005 to 2007. Patient demographics, clinicopathological characteristics, preoperative plasma fibrinogen levels and
median survival time (MST) were analyzed. Univariate and multivariate proportional hazard analysis of risk factors
were used.
Results: This study included 1196 patients (885 males and 311 females) with GC, more than half of whom had
advanced GCs. Radical lymph node dissection was performed in 71.6 % of these patients. MST was 41.9 ± 32.
4 months. Patient survival was significantly affected by family GC history (p <0.05), lymph node dissection mode
(p <0.001), tumor size (≥5 cm; p <0.001), tumor location (p < 0.001), poor tumor differentiation (p <0.001), tumor
histologic classification (p <0.001), extent of tumor invasion (p <0.001), number of metastatic lymph nodes
(p <0.001), advanced stage of disease (p <0.001), extended operation duration (>150 min; p <0.001), higher
operative bleeding volume (>200 ml; p <0.001), postoperative transfusion, preoperative serum fibrinogen levels,
CEA levels and CA 19-9 levels (p <0.001). Multivariate analysis indicated that the independent prognostic factors
significantly associated with poor survival included non-radical lymph node dissection, palliative lymph node
dissection, multi-organ involvement, advanced TNM stages, poor tumor differentiation, higher preoperative serum
fibrinogen levelsand higher CA19-9 levels.
Conclusions: Serum fibrinogen levels are positively correlated with advanced tumor stages and poor survival in GC
patients undergoing gastrectomy. Preoperative plasma fibrinogen levels are an independent risk factor for survival
in these patients. Serum fibrinogen is a useful biomarker for patients with clinically advanced GC.
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Background
Gastric cancer (GC) is one of the most common malig-
nancies and the third leading cause of cancer related
death worldwide [1]. Early diagnosis of GC is very diffi-
cult, and the majority of GC cases are diagnosed during
advanced stages with distant metastasis [2]. GC inci-
dence and mortality are particularly high in Asia [2].
According to the 2012 estimations of the World Health
Organization’s GLOBOCAN project, the age standard-
ized rates (ASR) of GC incidence and mortality in Asia
were 15.8 and 11.7 per 100,000, respectively [2].
Although advancements have been made in GC
chemotherapy and local control, patient prognosis re-
mains poor. The overall 5-year survival rate of patients
with GC is estimated to be between 10 and 30 % in US
and Europe. However, large regional differences exist be-
tween eastern and western nations. For instance, survival
rates in Japan have been reported to range from 50 to
70 % [3]. The most prominent prognostic factors affect-
ing the outcome and survival of GC patients are tumor
related factors, including tumor size, lymph node metas-
tasis, the degree of tumor cell differentiation, the extent
of tumor invasion and the presence of distant metastasis
[4–9]. Studies suggest that increasing tumor size,
advanced TNM stages and poor differentiation are all
important indicators of aggressive GC and predict worse
outcome [10, 11].
It is increasingly being recognized that, in addition to
tumor related factors, GC patient prognosis is also af-
fected by operation and patient related factors [12]. For
example, intraoperative blood loss and transfusion delay
are associated with worse post-surgical patient outcomes
[12]. Additionally, age, sex, inflammatory response, abnor-
mal blood coagulation and comorbidity have also been
correlated with poor survival and prognosis [13, 14].
Platelet and blood coagulation abnormalities occur fre-
quently in cancer patients. Thrombocytosis is considered
an important risk factor, and it is associated with poor
GC prognosis [14]. Fibrinogen is a 340-kDa glycoprotein
that is primarily produced by hepatic cells, and is an im-
portant clotting factor that helps regulate the hemostatic
pathway [15]. Fibrinogen is converted into fibrin, a final
product of hemostatic system, through the proteolytic
effect of thrombin [15]. Fibrinogen plays important
roles in blood coagulation, cell-cell adhesion and the
inflammatory response [15]. Elevated fibrinogen is a
well-known predictor of cardiovascular events and an
independent predictor of mortality in patients with
chronic kidney disease [16]. Additionally, recent studies
have suggested that elevated fibrinogen promotes can-
cer cell growth, progression and metastasis [17–21].
Furthermore, plasma fibrinogen levels have been asso-
ciated with tumor size, tumor invasion and lymph node
metastasis in patients with various cancers [15]. In
advanced GC, elevated fibrinogen levels have been associ-
ated with metastasis and tumor progression [15, 22].
Moreover, it has been reported that preoperative plasma
fibrinogen levels are a useful predictor of lymphatic
and hematogenous metastasis in GC [22, 23].
Hyperfibrinogenemia is increasingly being recognized
as an important risk factor influencing cancer develop-
ment and outcome. However, few reports have investi-
gated the use of fibrinogen as a prognostic biomarker
for GC patient survival. The primary aim of this study
was to evaluate the usefulness of preoperative serum
fibrinogen (FBG) as a biomarker for predicating tumor
progression and survival of patients with GC. Addition-
ally, we investigated the effects of multiple risk factors
on the survival of GC patients.
Methods
Patients
This retrospective study was approved by the institu-
tional review board of Harbin Medical University Can-
cer Hospital in China. The medical records of 1196 GC
patients who were treated in the hospital between 2005
and 2007 were reviewed. The inclusion criteria for this
study were: 1) age > 21 years; 2) histologically con-
firmed GC; and 3) GC treated via gastrectomy with D1,
D2 or more extended lymph node dissection. Exclusion
criteria included: 1) 3 months or less of follow-up data;
2) no preoperative plasma fibrinogen level data; 3)
acute or chronic inflammatory diseases, coagulation
disorders, chronic renal failure and acute or chronic
liver disease; and 4) orally administered anticoagulation
therapy.
For all patients enrolled in this study, we collected all
data concerning patient demographics (age, sex and fam-
ily history), clinicopathological characteristics, comor-
bidities, FBG levels, carcinoembryonic antigen (CEA)
levels, Carbohydrate antigen 19-9 (CA199) levels, opera-
tive factors (type of gastrectomy, extent of lymph node
dissection, operation time, intraoperative blood loss and
transfusion requirements) and tumor characteristics (lo-
cation, size, gross and pathological morphology, lymph
node metastasis, distant metastasis, disease stage and
median survival time, MST). Tumors were divided into
two major categories based on histological characteris-
tics: well-differentiated (papillary, well or moderately dif-
ferentiated adenocarcinomas) and undifferentiated
(poorly differentiated or undifferentiated adenocarcin-
omas, signet ring cell carcinomas and mucinous carcin-
omas) [11]. Surgical GC specimens were confirmed
histologically. Gastrectomy and other operational proce-
dures and reconstruction techniques were performed
based on standardized methods that have been previously
described [15]. Most of the radical lymphadenectomy
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means undergoing D2 lymph node dissection in our
research.
Fibrinogen, CEA and CA 19-9 measurements
Preoperative plasma fibrinogen, serum CEA and CA199
levels were examined in samples obtained from patients
before breakfast within 7 days prior to surgery. Plasma
fibrinogen levels were determined using the Clauss
method and the Dimension Vista System (Siemens,
Berlin, Germany) according to the manufacturer’s in-
structions. Normal preoperative plasma fibrinogen levels
were defined as being between 2.0 and 4.0 g/L [24]. Serum
fibrinogen concentrations between 1.5 and 4.0 g/L were
considered normal, and concentrations of 4.0 g/L or above
were considered hyperfibrinogenemic.
Follow-up
Post-surgical outcomes for the entire cohort were
followed for up to 5 years or until death. For the first
2 years after surgery, follow up examinations of all
patients were performed once every 3 months. After
2 years, follow up examinations were performed every
6 months. The 6-month follow up examinations contin-
ued for up to 5 years. During the follow up examina-
tions, physical examinations, laboratory tests, imaging
and endoscopy were performed.
Statistical analysis
Patient baseline characteristics were expressed as fre-
quencies and percentages. The cutoff value of 4.0 g/L
FBG was used to divide patients into low-and high-level
FBG groups. Values are reported as means ± standard
deviation (SD). Variables recorded for the patient groups
were compared using the chi-squared test, Mann–Whit-
ney U-test or Kruskal-Wallis test, as appropriate. Sur-
vival analysis (overall survival, OS) was performed using
the Kaplan-Meier method, and comparisons between
groups of interest were performed using the Log-rank
test. The Cox regression model was used in a multivari-
ate fashion to investigate the effects of selected con-
founding factors on the relationship between survival
time and clinical characteristics. The results were pre-
sented in terms of the median survival time and hazard
ratio (HR) with corresponding 95 % confidence intervals
(CI). To determine the best cutoff point for patient
survival prediction using FBG levels, receiver operating
characteristic (ROC) curve analysis was performed for
pre-treatment FBG levels, and an area under the curve
(AUC) with a 95 % confidence interval (CI) was derived.
A p value < 0.05 was considered statistically significant.
All analyses were performed using Statistical Analysis
System (SAS Institute, Cary, NC) software.
Results
Baseline patient characteristics
This study included 1196 GC patients, 885 (74.0 %) male
and 311 (26.0 %) female. Patient demographics and clini-
copathological characteristics are summarized in Table 1.
Seventy-two patients (6.0 %) were younger than 40 years
of age, 772 patients (64.6 %) were between 40 and
65 years of age and 352 patients (29.4 %) were older than
65 years of age. A majority of the patients (52.1 %) had
BMIs less than 18.5 kg/m2, and 117 patients (9.8 %) had
various comorbidities. Tumor sizes greater than 5 cm
were present in 61.4 % of patients, and in 63.8 % of the
patients, the tumors were located in the lower regions
of the stomach. Tumor involvement of multiple or-
gans was present in 4.6 % of patients.
More than half of the patients enrolled in this study
had advanced GCs. Seven-hundred and two patients
(58.7 %) had tumors that exhibited ulcerative infiltration,
and 42.9 % of patients had poor tumor differentiation.
The disease stage at the time of the GC diagnosis was
Stage 1 in 195 (16.3 %) patients, Stage 2 in 180 (15.1 %)
patients, Stage 3 in 395 (33.0 %) patients and Stage 4 in
426 (35.6 %) patients. Lymph node metastasis was N0 in
452 (37.8 %) patients, N1 in 196 (16.4 %) patients, N2 in
244 (20.4 %) patients and N3 in 304 (25.4 %) patients.
Metastasis was present in 75 (6.3 %) patients, and,
correspondingly, no metastasis was detected in 1121
(93.7 %) of the patients.
Most patients (71.6 %) underwent radical lymph node
dissection, and only a small proportion of the patients
underwent non-radical (20.9 %) or palliative (7.5 %)
lymph node dissection. Most patients experienced intra-
operative blood loss of less than 200 ml (81.7 %), and
only 24.7 % of the patients received postoperative
blood transfusions. The median survival duration was
55.62 months. Blood biomarker detection indicated
that most patients had normal levels of serum FBG
(78.3 %), CEA (77.9 %) and CA199 (92.2 %; Table 1).
Univariate analysis of prognostic factors
In this study, the MST of GC patients after surgery was
41.9 ± 32.4 months. To assess the prognostic factors af-
fecting patient survival, we conducted univariate analysis
of the MST in relation to the various demographic and
clinicopathological factors of the enrolled patients. The
univariate analysis indicated that gender, age, BMI and
the presence of comorbidities were not risk factors for
survival (all p > 0.05). However, other demographic and
clinicopathological factors were significantly associated
with patient survival. These factors included a family
history of GC (HR 0.8; p <0.05), the mode of lymph
node dissection (Non-radical, HR 4.74, p < 0.001; Pallia-
tive, HR 12.21, p < 0.001), tumor size (≥ 5 cm, HR 3.29,
p < 0.001), tumor location (Upper, HR 1.83, p < 0.001;
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Table 1 Baseline patient characteristics
Factor Variable No. of patients (%)
Total number of patients 1196 (100.0)
Patient-related Gender
Male 885 (74.0)
Female 311 (26.0)
Age (years)
<40 72 (6.0)
40–65 772 (64.6)
≥ 65 352 (29.4)
Body mass index (kg/m2)
<18.5 623 (52.1)
18.5–20 93 (7.8)
20–24 284 (23.7)
≥ 24 196 (16.4)
Comorbidity
No 1079 (90.2)
Yes 117 (9.8)
Family history
No 960 (80.3)
Yes 236 (19.7)
Fibrinogen (g/L)
≤ 4 887 (78.3)
>4 246 (21.7)
Carcinoembryonic antigen
<5 348 (77.9)
≥ 5 99 (22.1)
Carbohydrate antigen 19-9
<37 1103 (92.2)
≥ 37 93 (7.8)
Tumor-related Tumor location
Lower 762 (63.8)
Upper 184 (15.4)
Medium 249 (20.8)
Tumor size (cm)
<5 461 (38.6)
≥ 5 735 (61.4)
Multi-organ involvement
No 1141 (95.4)
Yes 55 (4.6)
Multifocal
No 1079 (97.6)
Yes 27 (2.4)
Gross morphology
Flat 142 (11.9)
Uplift 137 (11.4)
Table 1 Baseline patient characteristics (Continued)
Ulcerative 146 (12.2)
Infiltration ulcerative 702 (58.7)
Diffuse infiltration 69 (5.8)
T stage
1 195 (16.3)
2 180 (15.1)
3 395 (33.0)
4 426 (35.6)
N stage
N0 452 (37.8)
N1 196 (16.4)
N2 244 (20.4)
N3 304 (25.4)
Metastasis
No 1121 (93.7)
Yes 75 (6.3)
TNM
1 205 (17.1)
2 318 (26.6)
3 599 (50.1)
4 74 (6.2)
Differentiation
Poor 513 (42.9)
Medium 246 (20.6)
Signet ring 34 (2.8)
Mucus 47 (3.9)
Papillary 8 (0.7)
Mixed or other 348 (29.1)
Operation-related Operation time (in min.)
≤ 150 616 (51.5)
>150 580 (48.5)
Mode of lymph node dissection
Radical 856 (71.6)
Non-radical 250 (20.9)
Palliative 90 (7.5)
Cleared lymph node number
<15 667 (55.8)
≥ 15 529 (44.2)
Intraoperative blood loss (ml)
≤ 200 977 (81.7)
>200 219 (18.3)
Blood transfusion
No 901 (75.3)
Yes 295 (24.7)
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Medium, HR 2.03, p < 0.001), poor tumor differentiation
(HR 1; p < 0.001), histological classification of the tumor
(p < 0.001), extent of tumor invasion (p < 0.001), number
of metastatic lymph nodes (p < 0.001), advanced disease
stages (HR 50.32, p < 0.001), extended duration of the
operation (> 150 min, HR 1.17, p < 0.001), higher opera-
tive bleeding volume (> 200 ml, HR 1.61, p < 0.001),
postoperative transfusion (HR 1.64, p < 0.001), FBG levels
(> 4.0 g/L, HR 1.78, p < 0.001), CEA levels (≥ 5.0 g/L, HR
1.82, p < 0.001) and CA 19-9 levels (≥ 37.0 g/L, HR
1.84, p < 0.001). The results of the univariate analysis
are shown in Table 2.
Multivariate analysis of prognostic factors
To identify the independent risk factors that could be
used to predict MST, we performed multivariate
analysis of prognostic factors and MST using the Cox
proportional hazards model. Factors included in the
multivariate analysis included the mode of lymph node
dissection, the presence of multi-organ involvement,
the stage of the disease, FBG levels, CA199 levels and
tumor differentiation. The analysis indicated that sev-
eral of these independent prognostic factors were sig-
nificantly associated with poor GC patient survival. The
significantly associated factors included non-radical
lymph node dissection (HR 2.66; p < 0.0001; 95 % CI
2.20–3.22), palliative lymph node dissection (HR 16.97;
p < 0.0001; CI 9.07–31.72), multi-organ involvement
(HR 2.06; p < 0.0001; CI 1.50–2.84), advanced TNM
stages, poor tumor differentiation, higher FBG levels
(HR 1.36; p = 0.0008; CI 1.14–1.62) and higher CA199
levels (HR 1.39; p = 0.0115; CI 1.08–1.79; Table 3). Not-
ably, the T stage was not significantly associated with
poor prognosis.
The diagnostic value of serum FBG levels
To determine the diagnostic value of serum FBG levels,
ROC curve analysis was performed and an area under
the curve (AUC) with a 95 % confidence interval (CI)
was derived. When the FBG cut-off value was > 2.6 g/L,
the sensitivity was 81.3 % (95 % CI: 69.5–89.9) and the
specificity was 27.3 % (95 % CI: 24.7–30.1). When the
FBG cut-off value was ≤ 3.68 g/L, the sensitivity was
78.8 % (95 % CI: 74.9–82.4) and the specificity was
40.7 % (95 % CI: 36.9–44.6). Therefore, we set an FBG
cut off value of 4.0 g/L in this study (Fig. 1).
Serum FBG levels are positively correlated with tumor
progression and metastasis
The multivariate analysis described above indicated that
elevated serum FBG levels were an independent prog-
nostic factor of poor patient survival. To investigate the
correlations between serum FBG and the disease stage
of the tumor, we performed Chi-square analysis of FBG
levels in patients with different T, N and pathological
stages. We observed significant differences in the serum
FBG levels of patients with different T stages (F = 11.94,
p < 0.0001), N stages (F = 4.93, p = 0.0021) and patho-
logical stages (F = 16.13, p < 0.0001). Additionally,
correlation analysis indicated that serum FBG levels
were positively correlated with patient T stages (t = 4.63,
p < 0.0001), N stages (t = 3.83, p = 0.0001) and patho-
logical stages (t = 6.50, p < 0.0001; Table 4).
Serum FBG levels are positively correlated with survival
of patients
To study the correlations between serum FBG levels
and patient survival, we compared the overall survival
rates of patients with normal serum FBG levels with
the overall survival rates of patients with high serum
FBG levels. We observed that, after surgery, GC pa-
tients in the high FBG level group (> 4.0 g/L) had a
significantly lower survival rate when compared with
the normal FBG level group (≤ 4.0 g/L; p = 0.0009;
log-rank test; Fig. 2).
Discussion
In this comprehensive retrospective study of the risk
factors influencing GC patient survival after gastrec-
tomy, we analyzed patient-related, tumor-related and
operation-related demographic and clinicopathological
data from 1196 patients who were treated for operable
GC in Harbin Medical University Cancer Hospital be-
tween 2005 and 2007. The results of our study indicate
that many factors influence the survival rates and
survival time of post-surgical GC patients. However, the
most important finding reported by this study is that
serum FBG levels are positively correlated with the pro-
gression and metastasis of GC. Thus, our results indicate
that FBG is an independent risk factor that can be used
to predict GC patient survival. Additionally, our results
confirm the importance of other well-known tumor-
related and operation-related factors.
FBG is an acute-phase protein that regulates clotting
and fibrinolysis, and hyperfibrinogenemia has frequently
been linked with a number of malignancies [20, 21, 25].
It is thought that the link between hyperfibrinogenemia
and cancer may be related to the systemic activation of
the clotting system observed in many cancer patients
[26]. Two possible mechanisms underlying this relation-
ship include cancer cell driven stimulation of FBG levels
by direct activation of the clotting response to produce
procoagulant factors (including FBG), and indirect
stimulation of mononuclear cells to secrete these factors
[27]. A strong correlation between FBG and enlarged
tumor size, increased tumor growth, increased meta-
static potential and poor prognosis in various cancers is
increasing being recognized [17–21, 25]. Preston et al.
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Table 2 Univariate analysis of risk factors affecting patient survival
Factor Variable Survival months (means ± SE) HR (95 % CI) p value
Total 41.9 ± 32.4
Patient-related Gender
Male 41.0 ± 32.1 1
Female 44.4 ± 33.0 0. 87 (0.73–1.03) 0.1074
Age (years)
<40 47.1 ± 32.4 1
40–65 42.4 ± 32.7 1.15 (0.83–1.60) 0.4107
≥ 65 39.6 ± 31.6 1.32 (0.94–1.87) 0.1123
Body mass index (kg/m2)
<18.5 42.1 ± 33.5 1
18.5–20 36.5 ± 29.2 1.13 (0.86–1.49) 0.3774
20–24 42.5 ± 30.9 0.91 (0.75–1.10) 0.3137
≥ 24 42.8 ± 32.1 0.95 (0.77–1.17) 0.6183
Comorbidity
No 41.6 ± 32.1 1
Yes 43.9 ± 34.6 0.93 (0.72–1.21) 0.5909
Family history
No 41.3 ± 32.5 1
Yes 44.4 ± 32.0 0.80 (0.66–0.98) 0.0286
Fibrinogen (g/L)
≤ 4 45.7 ± 32.6 1
>4 30.8 ± 28.9 1.78 (1.49–2.11) < 0.0001
Carcinoembryonic antigen
<5 43.4 ± 29.3 1
≥ 5 31.7 ± 29.1 1.82 (1.38–2.38) < 0.0001
Carbohydrate antigen 19-9
<37 43.2 ± 32.6 1
≥ 37 26.4 ± 24.6 1.84 (1.44–2.35) < 0.0001
Tumor-related Tumor location
Lower 47.4 ± 32.7 1
Upper 34.2 ± 30.3 1.83 (1.50–2.23) < 0.0001
Medium 30.7 ± 28.7 2.03 (1.70–2.42) < 0.0001
Tumor size (cm)
<5 58.5 ± 30.0 1
≥ 5 31.5 ± 29.4 3.29 (2.75–3.94) < 0.0001
Multi-organ involvement
No 42.7 ± 32.3 1
Yes 24.3 ± 28.5 2.27 (1.68–3.07) < 0.0001
Multifocal
No 44.4 ± 32.0 1
Yes 55.8 ± 28.5 0.67 (0.38–1.19) 0.1721
Gross morphology
Flat 34.0 ± 36.0 1
Uplift 47.4 ± 33.1 0.56 (0.41–0.76) 0.0003
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Table 2 Univariate analysis of risk factors affecting patient survival (Continued)
Ulcerative 55.0 ± 32.3 0.42 (0.31–0.59) < 0.0001
Infiltration ulcerative 40.8 ± 30.8 0.71 (0.57–0.90) 0.0037
Diffuse infiltration 30.4 ± 29.1 1.09 (0.77–1.55) 0.6112
T stage
1 44.8 ± 37.0 1
2 64.1 ± 27.4 0.35 (0.25–0.51) < 0.0001
3 41.2 ± 30.4 1.20 (0.94–1.52) 0.1397
4 31.7 ± 28.8 1.80 (1.42–2.27) < 0.0001
N stage
N0 52.6 ± 33.4 1
N1 53.0 ± 31.2 1.12 (0.87–1.45) 0.3837
N2 35.6 ± 29.7 2.36 (1.91–2.92) < 0.0001
N3 23.8 ± 23.0 3.72 (3.06–4.53) < 0.0001
Metastasis
No 44.1 ± 32.2 1
Yes 8.7 ± 7.7 5.75 (4.48–7.38) < 0.0001
TNM
1 70.2 ± 25.2 1
2 56.4 ± 29.6 4.45 (2.80–7.07) < 0.0001
3 28.6 ± 26.5 15.14 (9.76–23.49) < 0.0001
4 8.8 ± 7.7 50.32 (30.71–82.46) < 0.0001
Differentiation
Poor 33.0 ± 31.1 1
Medium 55.0 ± 30.3 0.38 (0.30–0.48) < 0.0001
Signet ring 47.5 ± 30.5 0.49 (0.30–0.82) 0.0058
Mucus 49.8 ± 31.5 0.58 (0.39–0.86) 0.0064
Papillary 45.1 ± 32.6 0.54 (0.20–1.44) 0.2174
Mixed or other 44.0 ± 32.2 0.64 (0.53–0.76) < 0.0001
Operation-related Operation time (min.)
≤ 150 43.3 ± 32.9 1
>150 40.3 ± 31.8 1.17 (1.01–1.36) 0.0361
Mode of lymph node dissection
Radical 52.2 ± 30.8 1
Non-radical 18.8 ± 20.4 4.74 (4.00–5.62) < 0.0001
Palliative 7.2 ± 6.8 12.21 (9.52–15.67) < 0.0001
Cleared lymph node number
<15 40.5 ± 33.2 1
≥ 15 43.6 ± 31.3 0.81 (0.70–0.95) 0.0072
Intraoperative blood loss (ml)
≤ 200 44.1 ± 32.6 1
>200 31.7 ± 29.4 1.61 (1.35–1.93) < 0.0001
Blood transfusion
No 44.6 ± 32.3 1
Yes 33.4 ± 31.0 1.64 (1.39–1.93) < 0.0001
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[28] reported that fibrinogen production was elevated in
pancreatic adenocarcinoma patients. Shen et al. [20]
examined FBG levels in 567 patients with operable non-
small cell lung cancer and reported that serum fibrino-
gen was an independent prognostic factor. Patients with
hyperfibrinogenemia in the Shen et al. study had a
higher risk of disease progression and mortality when
compared with patients that had normal fibrinogen
levels [20]. Tanaka et al. [25] reported that preoperative
plasma fibrinogen levels higher than 450 mg/dL were an
independent risk factor of subsequent tumor recurrence
and cancer-specific survival in patients with localized
upper tract urothelial carcinomas. Additionally, Tanaka
et al. demonstrated that high plasma fibrinogen levels
predicted worse pathological features and positive lym-
phovascular invasion [20]. Lee et al. [15, 29] reported
that tumor size, tumor depth, tumor extent, lymph node
metastasis and poor patient survival were positively
correlated with preoperative plasma fibrinogen levels
in advanced GC.
To determine the diagnostic value of serum FBG
levels, ROC curve analysis was performed and an area
under the curve (AUC) with a 95 % confidence interval
(CI) was derived. We set an FBG cut off value of 4.0 g/L.
When the FBG cut-off value was ≤ 3.68 g/L, the sensitiv-
ity was 78.8 % and the specificity was 40.7 %. A previous
study reported that when plasma fibrinogen levels >
402 mg/dL were defined as hyperfibrinogenemia based
on ROC curve analysis, fibrinogen concentration had a
PPV of 92.73 % [30].
Table 3 Multivariate analysis of risk factors affecting patient
survival
Variable HR (95 % CI) p
Lymph node dissection
(radical vs. non-radical)
2.66 (2.20–3.22) < 0.0001
Lymph node dissection
(radical vs. palliative)
16.97 (9.07–31.72) < 0.0001
Multi-organ involvement
(yes vs. no)
2.06 (1.50–2.84) < 0.0001
T stage (2 vs. 1) 0.72 (0.44–1.16) 0.1744
T stage (3 vs. 1) 1.14 (0.74–1.78) 0.5501
T stage (4 vs. 1) 1.33 (0.86–2.04) 0.1965
N stage (1 vs. 0) 1.37 (0.96–1.97) 0.0851
N stage (2 vs. 0) 2.44 (1.61–3.70) < 0.0001
N stage (3 vs. 0) 3.22 (2.09–4.94) < 0.0001
Metastasis (yes vs. no) 81.97 (10.49–640.70) < 0.0001
TNM stage (2 vs. 1) 3.00 (1.71–5.26) 0.0001
TNM stage (3 vs. 1) 3.37 (1.68–6.76) 0.0006
TNM stage (4 vs. 1) 0.08 (0.01–0.60) 0.0148
Differentiation
(medium and good vs. poor)
0.65 (0.51–0.83) 0.0006
Differentiation
(mucous vs. poor)
0.53 (0.34–0.83) 0.0054
Differentiation
(papillary vs. poor)
0.94 (0.35–2.55) 0.9075
Differentiation
(mixed and others vs. poor)
0.90 (0.75–1.09) 0.2895
Differentiation
(Signet Ring vs. poor)
0.90 (0.54–1.49) 0.6717
Fibrinogen (g/L)
(>4 vs. ≤4)
1.36 (1.14–1.62) 0.0008
Carbohydrate antigen 19-9
(≥37 vs. < 37)
1.39 (1.08–1.79) 0.0115
Fig. 1 Receiver operating characteristic (ROC) curve analysis performed
using pre-operational fibrinogen (FBG) levels to determine the best cutoff
point for predicting the survival of gastric cancer patients. a When FBG
cutoff value was set > 2.6 g/L, the sensitivity was 81.3 %, the 95 %
confidence interval (CI) was 69.5–89.9; the specificity was 27.3 % and
the 95 % CI was 24.7–30.1; b When the FBG cutoff value was set≤
3.68 g/L, the sensitivity was 78.8 %, the 95 % CI was 74.9–82.4; the
specificity was 40.7 % and the 95 % CI was 36.9–44.6
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Our current study supports the hypothesis that plasma
FBG levels are positively correlated with the advanced T
stages, N stages and pathological stages of GC. Further-
more, our results indicate that FBG is an important
independent factor that influences the survival of GC
patients. These findings are consistent with the findings
of previous studies [15, 29] and indicate that elevated
fibrinogen levels are associated with advanced GC
metastasis and tumor progression [15, 22]. Therefore,
serum fibrinogen may be a useful biomarker for the
identification of patients with clinically advanced GC.
Additionally, preoperative plasma fibrinogen level is a
useful predictor of adjacent organ involvement in
advanced GC patients [15]. It may also be useful to
monitor serum FBG levels during ongoing patient man-
agement. This report does not discuss patient manage-
ment, and a future manuscript will discuss the effects of
various therapies on fibrinogen levels in patients with
gastric cancer. Although serum FBG is a valuable
marker, levels could be affected by underlying disease,
such as, for example, in cardiac infarction.
Hyperfibrinogenemia may help provide favorable con-
ditions for cancer cell metastasis via the lymphatic sys-
tem [22], and preoperative plasma fibrinogen levels are a
useful predictor of lymphatic as well as hematogenous
metastasis in GC [22, 23]. However, the molecular
mechanisms through which fibrinogen promotes tumor
metastasis remain unclear. Fibrinogen is a dimeric mol-
ecule and has various integrin and non-integrin binding
motifs. Because cancer cells usually produce an elevated
number of fibrinogen receptors (eg α5β1, αvβ3 integrins
and the ICAM-1 molecule), some scholars have pro-
posed that fibrinogen may facilitate tumor and host cell
interactions, thus facilitating tumor cell metastasis. An-
other possible metastasis promoting mechanism is the
fibrinogen-facilitated formation of large tumor cell ag-
gregates with platelet αIIbβ3 integrin receptors. By form-
ing these large aggregates, cancer cells are able to avoid
detection by the innate immune system and, thus, the
metastatic potential of the aggregated cells is increased
[23, 31, 32]. A third possible metastasis promoting
mechanism is caused by a positive feedback loop
Table 4 Correlations between serum FBG and tumor TNM stage
No. of
patients (%)
Chi-square
test
Fibrinogen (g/L)
(means ± SE)
Regression
analysis
T stage F = 11.94,
p < 0.0001
t = 4.63,
p < 0.0001
1 195 (16.3) 3.19 ± 0.97
2 180 (15.1) 2.94 ± 0.85
3 395 (33.0) 3.33 ± 1.01
4 426 (35.6) 3.45 ± 0.99
N stage F = 4.93,
p = 0.0021
t = 3.83,
p = 0.0001
N0 452 (37.8) 3.17 ± 0.94
N1 196 (16.4) 3.24 ± 1.02
N2 244 (20.4) 3.37 ± 1.00
N3 304 (25.4) 3.44 ± 1.00
Pathological
stage
F = 16.13,
p < 0.0001
t = 6.50,
p < 0.0001
1 205 (17.1) 2.94 ± 0.89
2 318 (26.6) 3.18 ± 0.95
3 599 (50.1) 3.46 ± 1.00
4 74 (6.2) 3.38 ± 1.02
Fig. 2 Overall survival according to pre-operational serum fibrinogen (FBG) levels. Gastric cancer patients with FGB > 4.0 g/L have a lower overall
survival rate when compared with patients with FGB < 4.0 g/L (p = 0.0009)
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between cancer induced inflammation and fibrinogen
levels. The increased systemic inflammatory response
caused by cancer progression greatly enhances the levels
of fibrinogen, and the elevated fibrinogen, in turn,
promotes cancer cell metastasis [22].
In addition to FBG levels, we also analyzed the levels
of CEA and CA19-9 in GC patients. Both CEA and
CA19-9 are well known GC biomarkers [3, 33]. In the
present study, we confirmed that patients with higher
CEA and CA19-9 levels had a greatly reduced survival
time. According to the multivariate analysis conducted
in our study, elevated serum CA19-9 levels were an in-
dependent predictor of poor survival in GC patients, but
CEA levels were not. However, our results indicate that
FBG levels may be a better GC biomarker when com-
pared with CEA and CA19-9 levels.
Interestingly, univariate analysis indicated that patient
related factors, including age, sex, BMI and comorbid-
ity, had no effect on patient survival. The only excep-
tion was a family history of GC. Regarding patient age,
the results of our analysis differ from a previous report
by Liang et al. [34]. In the Liang et al. study, the au-
thors claimed that patient age greater than 70 years was
an independent prognostic factor for GC after gastrec-
tomy, and elderly patients (OS: 22.0 %) had a signifi-
cantly lower 5-year OS rate when compared with
younger (OS: 36.6 %) and middle-aged patients (OS:
38.0 %). Inokuchi et al. [35] reported that comorbidity
predicted post-gastrectomy complications in patients
with large GC tumors. However, our results indicate
that patients both with and without comorbidities have
similar median survival times. The differences between
the results of our current study and the Inokuchi et al.
report is likely due to differences in the severity of
comorbidities in each patient population.
We found that patients with a family history of GC
have shorter survival times when compared with pa-
tients without any family history of GC (41.3 months vs.
44.4 months). This finding is in accordance with a report
from Liang et al. [36]. In the Liang et al. report, they
compared the clinicopathological characteristics of 91
patients with familial GC (FGC) and 293 patients with
sporadic GC (SGC). They reported that the 5-year over-
all survival rate in the FGC patients was significantly
lower than that in the SCG patients (25.6 % vs. 38.9 %,
p = 0.001). FGC was correlated with poor GC differenti-
ation and prognosis.
Various studies have suggested that tumor size not
only determines the extent of disease, tumor metastasis
and invasion, but that it also predicts patient survival
[13–15]. Tumor size has been reported to be an inde-
pendent prognostic factor, and a modified TNM system
based on tumor size accurately predicts patient survival
[11]. In the present study, univariate analysis suggested
that patients with tumors larger than 5 cm had a shorter
survival time when compared with patients that had tu-
mors smaller than 5 cm. Although there were significant
differences, tumor size was not found to be an inde-
pendent predictor of patient survival by our multivariate
analysis. Our study agrees with the report from Lu et al.
[10]. However, other reports have suggested that tumor
size is an independent predictor of patient survival [37].
In addition to tumor size, tumor location is another
factor that may influence patient survival. We found that
the tumors located in the upper and medium gastric
areas were associated with a poor patient prognosis.
However, multivariate analysis did not find that tumor
location was an independent factor. In contrast with
tumor size and location, multivariate analysis indicated
that poor differentiation, deep invasion and lymph node
metastasis were independent factors.
Lymph node metastasis and advanced TNM stage are
considered the most important factors for the prediction
of recurrence and survival in GC patients [4–9]. Lymph
node metastases are observed in more than 50 % of GC
patients at the time of diagnosis. The 5-year survival rate
of patients with lymph node metastasis is reported to be
approximately 30 % [9]. The analysis reported here con-
firms that lymph node metastasis is a critical prognostic
factor in GC patients, and that lymph node metastasis
correlates strongly with shorter survival time and poor
patient prognosis. In addition to lymph node metastasis,
we also found that GC invasion of other organs was an
independent risk factor for survival.
Surgery is an important factor in the treatment of GC
patients, and operation related factors are another type
of important risk factor associated with patient mortality
and survival. Operational factors that we examined in
the present study include the mode of lymph node dis-
section, operational time, intraoperative blood loss and
transfusion treatment. Our analysis indicated that radical
lymph node dissection is an independent favorable factor
for GC patient survival. Patients that received radical
lymph node dissection survived as long as 52 months,
while those who did not receive the therapy survived less
than one and half a years. A previous report suggested
that intraoperative blood loss was an independent prog-
nostic factor for GC patients who had undergone cura-
tive resection [12]. Reducing intraoperative blood loss
improved the long-term outcome of GC patients treated
with curative gastrectomy [12]. In the present study, we
did not conduct multivariate analysis on intraoperative
blood loss; therefore, we are unable to conclude that in-
traoperative blood loss is an independent risk factor for
survival. However, we do confirm that certain oper-
ational factors (operational time more than 150 min,
blood loss more than 200 ml and insufficient or delayed
blood transfusion) are associated with GC patient
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survival. Notably, the receipt of a blood transfusion can
significantly shorten survival time.
Although this is a comprehensive study related to
FBG and other prognostic factors in GC patients, we
did not conduct further analysis of risk factors that
could affect serum FBG levels.
Conclusions
Preoperative hyperfibrinogenemia is correlated with GC
progression, and FBG levels are an independent risk fac-
tor of GC patient survival in patients with operable GC.
Additionally, serum fibrinogen is a useful biomarker for
patients with clinically advanced GC. Furthermore,
tumor and operative factors (non-radical lymph node
dissection, multi-organ involvement, advanced TNM
stages and poor tumor differentiation) and CA199 levels
are independent prognostic factors that are also associ-
ated with poor GC patient survival after gastrectomy.
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